Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00928746 · ClinicalTrials.gov registry record · Phase 3
Actuation Indicator Trial in Patients With COPD
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 142
- Enrollment target
NCT00928746 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 142 participants.
The verdict
NCT00928746, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 142 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the performance, accuracy, and handling of the actuation indicator in patients with COPD. The actuation indicator is integrated into mouthpiece of the ipratropium bromide HFA inhalation aerosol device. As part of Boehringer Ingelheim's program to qualify an actuation indicator for use with the ipratropium bromide HFA inhalation aerosol device, this study is intended to complement the results from the ongoing in-vitro studies.
Interventions
- DEVICE Ipratropium bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00928746
The ClinicalTrials.gov registry entry for NCT00928746 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ipratropium bromide is the first listed.
NCT00928746 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00928746 about?
NCT00928746 is a clinical study titled "Actuation Indicator Trial in Patients With COPD". The primary objective of this study is to evaluate the performance, accuracy, and handling of the actuation indicator in patients with COPD. The actuation indicator is integrated into mouthpiece of the ipratropium bromide HFA inhalation aerosol device. As part of Boehringer Ingelheim's program to qu...
What is the current status of trial NCT00928746?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 142 participants. The study started on 2009-06.
What interventions are being tested in trial NCT00928746?
The interventions under investigation include: Ipratropium bromide (DEVICE).
Who is sponsoring clinical trial NCT00928746?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.